Analysts Set The Beauty Health Company (NASDAQ:SKIN) PT at $2.81

Shares of The Beauty Health Company (NASDAQ:SKIN) have earned an average recommendation of “Hold” from the six research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $2.8125.

A number of analysts recently weighed in on SKIN shares. Stifel Nicolaus increased their price objective on shares of Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a report on Friday, August 1st. Cowen reaffirmed a “hold” rating on shares of Beauty Health in a report on Monday, September 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Beauty Health in a report on Wednesday, October 8th. Wall Street Zen raised shares of Beauty Health from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, TD Cowen increased their price objective on shares of Beauty Health from $2.00 to $2.50 and gave the stock a “hold” rating in a report on Monday, September 22nd.

Beauty Health Stock Down 0.7%

Shares of NASDAQ:SKIN opened at $1.33 on Friday. The stock has a market capitalization of $168.67 million, a price-to-earnings ratio of -4.75 and a beta of 1.21. Beauty Health has a 1-year low of $0.78 and a 1-year high of $2.69. The company’s fifty day moving average is $1.98 and its two-hundred day moving average is $1.71. The company has a debt-to-equity ratio of 4.91, a quick ratio of 4.15 and a current ratio of 5.15.

Beauty Health (NASDAQ:SKIN) last issued its earnings results on Thursday, August 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The company had revenue of $78.20 million for the quarter, compared to analysts’ expectations of $74.67 million. Beauty Health had a negative net margin of 6.13% and a negative return on equity of 32.82%. Beauty Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts anticipate that Beauty Health will post -0.25 EPS for the current year.

Hedge Funds Weigh In On Beauty Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Mirabella Financial Services LLP grew its position in Beauty Health by 5.0% in the 2nd quarter. Mirabella Financial Services LLP now owns 12,861,549 shares of the company’s stock valued at $24,566,000 after buying an additional 614,602 shares in the last quarter. Geode Capital Management LLC grew its position in Beauty Health by 27.5% in the 2nd quarter. Geode Capital Management LLC now owns 2,302,784 shares of the company’s stock valued at $4,399,000 after buying an additional 496,963 shares in the last quarter. Soleus Capital Management L.P. bought a new position in Beauty Health in the 2nd quarter valued at about $1,910,000. Prescott Group Capital Management L.L.C. grew its position in Beauty Health by 29.2% in the 2nd quarter. Prescott Group Capital Management L.L.C. now owns 835,939 shares of the company’s stock valued at $1,597,000 after buying an additional 189,141 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Beauty Health by 5.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 665,706 shares of the company’s stock valued at $892,000 after buying an additional 31,880 shares in the last quarter. Institutional investors own 93.26% of the company’s stock.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.